Last reviewed · How we verify
Omburtamab I-131
At a glance
| Generic name | Omburtamab I-131 |
|---|---|
| Sponsor | Pediatric Brain Tumor Consortium |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (PHASE2)
- 131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults
- A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum (PHASE2)
- 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases (PHASE2, PHASE3)
- Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer (PHASE1)
- 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Omburtamab I-131 CI brief — competitive landscape report
- Omburtamab I-131 updates RSS · CI watch RSS
- Pediatric Brain Tumor Consortium portfolio CI